# 2025-10549: FDA Considers Easier Path for Certain Cancer-Linked Tests

2025-10549, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product, is a Federal Register proposed rule from Health and Human Services Department, Food and Drug Administration published 2025-06-11, effective Either electronic or written comments on the proposed order must be submitted by August 11, 2025; see section X of this document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order based on this proposed order.; PRIA reads it as touching household money (as of 2026-10-30).

- Canonical: https://policyrisk.com/federal-register/2025-10549
- As of: 2026-10-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-10549
- Title: Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 24540
- Published: 2025-06-11
- Effective: Either electronic or written comments on the proposed order must be submitted by August 11, 2025; see section X of this document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order based on this proposed order.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-30

## In one line

FDA Considers Easier Path for Certain Cancer-Linked Tests

## Summary

The FDA wants to change the rules for certain cancer test systems called in situ hybridization (ISH) tests. These tests will move from a strict approval process to a simpler one with special safety rules, making it easier and faster for companies to get them to doctors and patients. Labs and companies using or making these tests should get ready to comment by August 11, 2025, and expect new rules soon that could save time and money.

## Abstract

The Food and Drug Administration (FDA) is proposing to reclassify in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK) from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for this device type.

## Effects PRIA read

- Manufacturers: Shift from PMA to 510(k): benefit, high. The FDA proposes to reclassify certain in situ hybridization (ISH) oncology test systems from class III (requiring a premarket approval (PMA)) into class II, so manufacturers would submit a premarket notification (510(k)) instead of a PMA. The rule says the 510(k) pathway is generally less burdenso…
- Patients: Potentially faster, wider access to ISH tests: benefit, high. FDA states the reclassification may provide more timely access to these ISH oncology tests and could enable more manufacturers to develop them so patients benefit from increased access to appropriately safe and effective tests. The proposal says this change could result in shorter premarket review…
- Special controls to reduce false test risks: benefit, medium. FDA proposes specific 'special controls' for these ISH oncology test systems to address risks the Agency identified—such as false positive or false negative results, failures to perform as intended, and incorrect interpretation of results—so that these devices, with special controls plus general co…
- Manufacturers: Use of Predetermined Change Control Plans: benefit, medium. FDA notes manufacturers may use Predetermined Change Control Plans (PCCPs) to implement certain future device modifications without submitting a new 510(k) for each significant change, if the PCCP is reviewed and authorized by FDA under section 515C of the FD&C Act.
- 510(k) submissions will still be required: mixed, low. FDA explicitly states it does not intend to exempt these proposed class II ISH devices from premarket notification; if the order is finalized, persons intending to market these devices must submit a 510(k) and receive clearance before marketing.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-10549 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/11/2025-10549/hematology-and-pathology-devices-reclassification-of-in-situ-hybridization-test-systems-for-use-with)
- [2025-10549 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-11/pdf/2025-10549.pdf)

## Related
- [Previous: 2025-10548, Air Plan Approval; West Virginia; 2024 Amendments to West Virginia's Ambient Ai…](https://policyrisk.com/federal-register/2025-10548)
- [Next: 2025-10477, Lower 37 GHz Band and Use of Spectrum Bands Above 24 GHz for Mobile Radio Servi…](https://policyrisk.com/federal-register/2025-10477)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-10549 (as of 2026-10-30).
